Korean J Intern Med.  2014 Mar;29(2):250-252. 10.3904/kjim.2014.29.2.250.

Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma

Affiliations
  • 1Division of Hematology and Oncology, Department of Internal Medicine, Cancer Center Dongnam Institute Radiological and Medical Sciences, Busan, Korea.
  • 2Division of Hematology and Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. lkhee@med.yu.ac.kr
  • 3Department of Laboratory Medicine, Yeungnam University College of Medicine, Daegu, Korea.

Abstract

No abstract available.

Keyword

Chronic myeloid leukemia; Diffuse large B-cell lymphoma; Therapy-related

MeSH Terms

Adult
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Benzamides/therapeutic use
Bone Marrow Examination
Chemoradiotherapy
Cyclophosphamide/administration & dosage
Doxorubicin/administration & dosage
Humans
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis/drug therapy/genetics/pathology
Lymphoma, Large B-Cell, Diffuse/*diagnosis/pathology/therapy
Male
*Neoplasms, Second Primary
Piperazines/therapeutic use
Positron-Emission Tomography
Prednisolone/administration & dosage
Protein Kinase Inhibitors/therapeutic use
Pyrimidines/therapeutic use
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Vincristine/administration & dosage
Whole Body Imaging/methods
Benzamides
Cyclophosphamide
Doxorubicin
Piperazines
Prednisolone
Protein Kinase Inhibitors
Pyrimidines
Vincristine
Full Text Links
  • KJIM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr